• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BD

BD inks $85M settlement over Alaris defect disclosure claims

December 26, 2023 By Sean Whooley

BD Alaris Infusion System updated FDA clearance

BD (NYSE:BDX) announced that it filed settlement documents for an $85 million agreement to resolve claims regarding its Alaris infusion pump technology. The Alaris system has been much maligned over the past few years. Its troubles date back to a Class I recall in early 2020. The recall, which centered around multiple system errors, software […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Legal News, Technology Tagged With: BD

BD recalls more Alaris pumps due to compatibility issues with Cardinal Health syringes

December 4, 2023 By Sean Whooley

BD Alaris Infusion System updated FDA clearance

The FDA determined that another recall of BD (NYSE:BDX) Alaris infusion pumps is Class I, the most serious kind. In the latest Alaris recall, the company cites compatibility issues with Cardinal Health Monoject syringes. The issue mainly relates to changes made to the products by Cardinal Health. It affects more than 1 million total devices. […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Recalls, Regulatory/Compliance Tagged With: BD, Cardinal Health, FDA

Embecta increases 2023 guidance, reports closed-loop insulin delivery tech progress

August 8, 2023 By Sean Whooley

BD Diabetes Spinoff Embecta

Embecta (Nasdaq:EMBC) shares rose this morning as it increased its full-year guidance and shared an update on its automated insulin delivery technology. The company also reported third-quarter results that came in ahead of the consensus forecast. Shares of EMBC ticked up 3.1% at $22.27 apiece in early-morning trading today. MassDevice’s MedTech 100 Index — which […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Technology, Wall Street Beat Tagged With: BD, embecta

FDA clears updated BD Alaris infusion system after long-term commercial hold

July 21, 2023 By Sean Whooley

BD Alaris Infusion System updated FDA clearance

BD (NYSE:BDX) announced today that the FDA granted 510(k) clearance for its updated Alaris infusion system. Shares of BDX closed out Friday evening priced at $264.84 each. They ticked up significantly after market close on the back of the Alaris news, rising 5.9% to $280.40 apiece. Clearance enables both remediation and a return to full […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Technology Tagged With: Alaris, BD, FDA

8 drug delivery innovations you should know

July 20, 2023 By Sean Whooley

8 drug delivery innovations you need to know 2023

Innovations in drug delivery never stop, and over the past 12 months or so a wide variety have been in the spotlight. Constant progress continues in the diabetes space, both in the form of insulin delivery and other drug delivery methods. Elsewhere, we see implants, patches, syringes and more showcasing the many ways we can […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Technology Tagged With: BD, Beta Bionics, biocorp, Humacyte, Innovation Zed, Insulet, Juvenile Diabetes Research Foundation (JDRF), Micron Biomedical, mit, Schott Pharma, Sernova Inc, Stevanato Group, Tandem Diabetes Care, tidepool, Vivani Medical, Ypsomed

BD discloses 8 cybersecurity vulnerabilities with Alaris infusion system

July 13, 2023 By Sean Whooley

BD Alaris with Guardrails Suite MX

BD (NYSE:BDX) today voluntarily posted a product security bulletin for a number of vulnerabilities with its Alaris infusion system. Franklin Lakes, New Jersey-based BD recently identified eight vulnerabilities. These vulnerabilities are associated with the BD Alaris system with Guardrails Suite MX, versions 12.1.3 and earlier. The company discovered the vulnerabilities through routine internal security testing […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Regulatory/Compliance, Technology Tagged With: Alaris, BD, Cybersecurity

BD is cutting 60 jobs at Ireland syringe manufacturing facility

July 5, 2023 By Sean Whooley

This is the logo of BD.

BD (NYSE: BDX) announced plans to eliminate 60 positions at its manufacturing facility based in Drogheda, Ireland. A statement provided by a BD spokesperson confirmed a targeted reduction of 60 positions due to a combination of factors. These include the effects of the COVID-19 pandemic and the company’s spinoff of its diabetes business, Embecta. The […]

Filed Under: Business/Financial News, Drug-Device Combinations Tagged With: BD

BD continues to expand in Ireland

June 5, 2023 By Sean Whooley

BD Enniscorthy Rendering (1)

BD (NYSE:BDX) announced that it opened a new facility in Ireland and committed a further investment within the country. Last week, the company held a grand opening ceremony for a new $4.3 million (€4 million) R&D facility in Blackrock, Dublin. BD also announced an additional $32.1 million (€30 million) investment to expand its Enniscorthy, Wexford […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Vascular Tagged With: BD

BD expands availability of all-in-one flush pre-filled syringe

May 23, 2023 By Sean Whooley

BD PosiFlush SafeScrub Syringe

BD (NYSE:BDX) announced today that it expanded customer availability for its all-in-one pre-filled flush syringe. Franklin Lakes, New Jersey-based BD designed its PosiFlush SafeScrub syringe with an integrated disinfection unit. It reinforces compliance with infection prevention guidelines, simplifying nursing workflow. BD built the active disinfection unit right into the tip cap of the PosiFlush SafeScrub […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured Tagged With: BD

Embecta stock rises on Q2 results, reports progress on automated insulin delivery tech

May 12, 2023 By Sean Whooley

BD Diabetes Spinoff Embecta

Embecta (Nasdaq:EMBC) shares ticked up today on second-quarter results that topped the consensus forecast, leading to a guidance increase. Shares of EMBC grew 2.1% to $29.52 apiece in early-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 0.1%. The Parsippany, New Jersey-based diabetes technology […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Technology, Wall Street Beat Tagged With: BD, embecta

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Interim pages omitted …
  • Page 7
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS